One Stock to Buy and Hold

Summit Therapeutics (NASDAQ: SMMT) has seen its shares soar over 1,500% in the past three years, despite being unprofitable and generating no revenue, leading to a market cap of $15.6 billion. This remarkable rise is largely attributed to significant advancements in its leading pipeline candidate, ivonescimab, suggesting a promising future for the biotech company.

Want More Context? 🔎